

Sharon D. Mitchell, Attorney at Law
SD Mitchell & Associates, PLC
829 Harcourt Rd. · Grosse Pointe Park, Michigan 48230
57492 Onaga Trail · Yucca Valley, California 92284
(248) 515-6035 (Phone) · (248) 751-6030 (Facsimile) · sharondmac2013@gmail.com

**Admitted in Michigan*

15 April 2022

OTC Markets Group, Inc.
304 Hudson Street
Second Floor
New York, New York 10013

Re: CeCors, Inc. information on OTC Disclosure and News Service

Dear Sir or Madame:

I have been retained by CeCors, Inc., a Nevada corporation (the "Company") for the limited purpose of rendering an opinion as to whether there is adequate current information available on the OTC Disclosure and News Service regarding the issuer and related matters. As such, OTC Markets Group is entitled to rely on such opinion in determining whether the issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933.

In connection with this opinion I have examined the corporate organizational documents of the Company, including, but not limited to, the following:

1. The Company's Certification of Incorporation;
2. Articles of Incorporation;
3. The Company's Annual Report with Financial Statements for the period ended December 31, 2021, and filed on April 4, 2022;
4. The Company's third Quarter Report with Financial Statements for the period ended September 30, 2021, and filed on November 19, 2021;
5. The Company's second Quarter Report with Financial Statements for the period ended June 30, 2021, and filed on August 14, 2021;
6. The Company's first Quarter Report with Financial Statements for the period ended March 31, 2021, and filed on May 20, 2021;
7. The Company's Annual Report with Financial Statements for the period ended December 31, 2020, and filed on March 23, 2021; and
8. The Guidelines for Providing Adequate Current Information as published by Pink OTC Markets, Inc.

The Company's consolidated unaudited financial statements, for the period ending December 31, 2021, were prepared in-house by Li Shen, CGA, of The Accounting Connection, located at 145-251 Midpark Blvd., S.E., Calgary, Alberta T2X 1S3 Canada and are not audited. The financial statements are prepared in conformity with accounting principles generally accepted in the United States. In all material respect, the financial statements filed with the OTC Market Groups, fairly present the financial position and results of operations of the Company, as well as cash flows, for the period presented.

The Company's transfer agent is Pacific Stock Transfer Co, an SEC registered transfer agent and located at 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119. The method used to obtain the number of outstanding shares as set forth in the Annual Report for the period ended December 31, 2021, was obtained via transfer agent verification on the OTC Pink, and the result of the following transactions:

# OF I/O	DATE	# OF SHARES	TYPE OF SHARES	NAME	REASON	EXEMPTION
Common Shares 209,767,672 Preferred Shares N/A	12/31/2019					
	1/1/2021	3,000,000	Common	Epione Ltd (Harjot Mehta & Noah Mirza)	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	3,000,000	Common	Jarz Investments Ltd. (Harvey Panesar)	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	3,000,000	Common	Strategic Relations Consulting Inc. (Moin Mirza)	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	3,000,000	Common	1923774 Alberta Ltd. (Danielle Nanda)	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	138,750,000	Common	Sukhinderpaul Kalsi	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	138,750,000	Common	Amar Bhatal	Acquisition Agreement, PsyKey Inc.	Reg S
	1/1/2021	500,000	Common	Guy Patrick Ratchford	Acquisition Agreement, PsyKey Inc.	Reg S
	7/13/2021	187,166	Common	Unknown	True up shares issued by TA upon review of records from previous TA	
Common Shares 499,954,838 Preferred Shares N/A	12/31/2021					

CeCors, Inc. was incorporated on April 16, 2002, in the state of Nevada as Expert Systems, Inc. The Company changed its name to Foldera Inc. on February 13, 2006, and from Foldera Inc., to CeCors, Inc. on August 12, 2008. The Company filed an application with FINRA to change its name to PsyKey, Inc. on August 10, 2021; to date, FINRA has not finished processing the application.

On December 31, 2020, the Board of Directors and controlling shareholders of the Company approved an increase of the authorized common stock to 500,000,000 common shares, par value \$0.001. Concurrently, the shareholders of the Company appointed new officers and directors and approved the acquisition of PsyKey, Inc., a federally incorporated Canadian corporation, (“PsyKey”) resulting in a change of management and control. Under the terms of the purchase agreement between the Company and the shareholders of PsyKey, the Company acquired 100% of the outstanding shares of PsyKey in exchange for a total of 290,000,000 shares of the Company’s common stock. The following individuals were elected directors and appointed as officers: Amar Bhatl, director, President and Secretary, Sukhinder Kalsi, director, Chief Financial Officer and Treasurer and Guy Patrick Ratchford, director, also resulting in a change in management.

PsyKey Inc., the Company’s wholly owned subsidiary, is in the business of research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations, for use in its premium quality functional product lines to help improve and optimize everyday life. PsyKey is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the fast-evolving psychedelic market.

During the fiscal year ended December 31, 2021, the Company agreed to pay certain software development consultants a total of \$500,000 for the work product related to currently in-development APP, “PsyKey Live”. The App will provide counselling on demand at any time and location with registered psychologists in every area of mental wellness, allowing individuals to take control of their mental health. Offering simple, direct access to caring mental health professionals for all conditions, from daily challenges to more severe treatments, the App will allow users to book an appointment on their phone or desktop to receive immediately counseling. The Company expects the App to be live on the Apple Store and Google in the coming months. Revenue will be generated on a commission basis per appointment booked, and also from in App advertising of health-related products and featured clinics.

Further in May 2021, the Company, through its wholly owned subsidiary, PsyKey, entered into a definitive agreement to form an exclusive strategic partnership with MycoVita Canada Inc. (“MycoVita”), that is expected to accelerate the growth and market share for both companies, in the fast-growing mycology-based markets. The partnership is undertaken through a 51% controlled subsidiary of PsyKey, Fungi Co Ltd., a Canadian federal incorporation, with the purpose of the partnership being the research, development, and commercialization of Mycology based formulations, products, and therapeutics, as well as the development of innovative sustainable food production strategies. Recently the Company has commenced operations in Fungi through the issuance of its first purchase orders to MycoVita for raw materials, which materials are expected to arrive in Spring 2022. The Company has also received its first customer purchase order in December 2021 for 1,850 boxes of coffee pods for delivery in Spring 2022.

Subsequent to December 31, 2021, the Company acquired a 100% equity interest in Nutra-Rox LLC (“NRX”), a company incorporated in Texas. NRX is a disruptive thought leader in the dietary supplement industry, specializing in the research, development, manufacturing, and distribution of nutraceutical formulations utilizing a unique, patent-pending carbonated crystal technology. Manufactured using a

proprietary process, these “popping crystals” serve as an alternative delivery method for a wide variety of ingredients including vitamins, minerals, nutraceuticals, antioxidants, natural botanicals, and time-tested herbal extracts. Effervescent carbonated crystals activate by dissolving easily in the mouth without chewing or water, while providing a fun, multi-sensory popping experience for consumers. Ideal for anyone who experience pill fatigue from swallowing conventional tablets and capsules or for those preferring an alternative to gummy vitamins. Formulated for amazing taste, Nutra-Rox develops innovative popping crystal product formulations for energy, focus, brain health, general wellness, and immunity. The Nutra-Rox acquisition brings shareholder value by providing the Company expanded novel product offerings, sales, and distribution.

There are currently 324,454,838 shares of CeCors, Inc. common stock outstanding as verified on the OTC Market site by the transfer agent, which is consistent with the corporate records of the issuer.

In connection with the opinion expressed herein, I have made such examination of law, as I considered appropriate for such purposes, and have relied entirely upon documents and certificates delivered to me, and which I deemed appropriate for purposes of rendering this opinion. In examining the documents, I have assumed the genuineness of signatures, the authenticity of documents submitted as originals, the conformity with originals of all documents furnished as copies, and the correctness of the facts set forth in such documents. During the course of my review, nothing led me to question the authenticity of any of the documents or facts contained herein. To that end, I am of the opinion that:

1. The current information posted by the Company constitutes adequate current public information and is publicly available as those terms are defined within the meaning of Rule 144(c)(2) under the Securities Act; the information includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934 as amended;
2. The aforementioned information as posted through the OTC Disclosure and News Service complies as to form and content with the OTC Markets Group, Inc. Guidelines for Providing Adequate Current Information as published by the OTC Market Groups, Inc.;
3. To the best of my knowledge, neither counsel, nor the members of management, the record owner of the Company, or any holder of 5% or more of the Company’s securities are currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws;
4. I have personally met (via video Zoom Teleconference call, with government issued identification (i.e. Alberta, Canada Driver’s License) in front of me, with the following officers and directors of the Company: Amar Bhatal, Chief Executive Officer, and a Sukhinder Paul Kalsi, Chief Financial Officer;
5. The Company’s transfer agent is Pacific Stock Transfer Co., located at 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119, and is registered with the Securities and Exchange Commission. The number of issued and outstanding shares was confirmed to me via transfer agent verification on the OTCMarkets site on April 13, 2022; and
6. To the best of my knowledge, and pursuant to review of publicly filed documents, the Company is not a “shell company” as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

The opinions and conclusions expressed herein are based upon the facts that have been provided to me by the Company and are based on the accuracy of the facts and representations of the Company. In reaching my conclusions, I have personally met Amar Bhatal, Chief Executive Officer, and Sukhinder Paul Kalsi,

OTC Markets Group, Inc.
Re: CeCors, Inc. (CEOS)
15 April 2022
Page 5 of 5


Chief Financial Officer, of CeCors, Inc., and have exchanged numerous emails and telephone conversations with corporate management. I have assumed the genuineness and authenticity of all documents provided to me; to the best of my knowledge I believe all sources to be reliable.

I am a resident of the United States and am licensed and authorized to practice law in the State of Michigan. This letter applies to the laws of the United States of America. I am allowed to practice before the Securities and Exchange Commission, and I have not been prohibited from practicing before it. I am the Company's SEC counsel with regard to compliance matters and public filings. I do not own any common or preferred stock of CeCors, Inc., and I do not anticipate receiving any in the immediate future.

I am not currently, nor have I been in the past five years (nor at any time), the subject of an investigation, hearing, or proceeding by the SEC, the US Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency. Furthermore, I am not currently, nor have I been in the past five years (nor at any time) suspended or barred from practicing in any state or jurisdiction, nor have I been charged in a civil or criminal case.

This opinion is rendered in conjunction with the Company's current disclosure documents and may be posted on the OTC Disclosure and News Service, for viewing by the public and regulators; however, only OTC Markets Group is entitled to rely on this opinion.

With best regards,



Sharon D. Mitchell

/

cc: Amar Bhatal, CEO
Sukhinderpaul Kalsi, CFO